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Abstract 
Objectives: Evaluate the efficacy and tolerability of itraconazole plus terbinafine for refractory onychomycosis. This is a prospective 
clinical trial. Patients with proven Trychophyton rubrum onychomycosis of toenails were enrolled; the treatment consisted of weekly 
administration: itraconazole 200mg/day and terbinafine 250mg/day, for four months. Results: Thirty-two patients with onychomycosis 
were studied. Twenty-eight cases had distal subungual onychomycosis and 4 total dystrophic onychomycosis. At the end of the follow-up 
17/32 patients had clinical and mycologic cure (53.12%), 5 had clinical improvement only (15.6%), and 10 (31.2%) failed.  
Conclusion: Weekly alternate therapy with itraconazole + terbinafine represents a safe rescue treatment. 
 
Streszczenie 
Cel:  Ocena  skuteczności  i  tolerancji  itrakonazolu  plus  terbinafiny  w  opornej  na  leczenie  grzybicy  paznokci.  Jest  to  prospektywne 
badanie kliniczne. Pacjentów z potwierdzoną grzybicą paznokci wywołaną przez Trychophyton rubrum zakwalifikowano do badania; 
leczenie polegało na cotygodniowym przyjmowaniu: itrakonazol 200 mg/dobę i terbinafiny 250mg/dobę, przez cztery miesiące.  
Wyniki:  Przebadano  trzydziestu  dwóch  pacjentów  z  grzybicą  paznokci.  Dwadzieścia  osiem  przypadków  miało  dystalną 
podpaznokciową grzybicę paznokci, a czterech całkowicie dystroficzną grzybicę paznokci. Pod koniec obserwacji 17/32 pacjentów było 
wyleczonych klinicznie i mykologicznie (53,12%), u 5 uzyskano tylko poprawę stanu klinicznego (15,6%), a u 10 (31,2%) leczenie nie 
powiodło  się.  Wnioski:  Cotygodniowa  zastępcza  terapia  itrakonazol  +  terbinafina  stanowi  bezpieczną  metodę  leczenia  w  takich 
pryzpadkach. 
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Introduction 
Onychomycosis  is  the  most  frequent  nail 
disorder.  Its  etiology  includes  three  agents: 
dermatophytes,  yeasts  and  molds.  Dermatophytic 
onychomycosis is the most frequent type and is caused 
by  Trichophyton  rubrum.  Most  cases  occur  in  the  toe 
nails and are seen more frequently in adults [1-4]. 
The  treatment  of  onychomycoses  has  experienced 
changes  in  the  past  fifteen  years  as  a  result  of  the 
development  of  new  oral  antifungals,  particularly  the 
triazole  derivative  itraconazole  and  the  allylamine 
terbinafine[5,6]. Overall, both treatments result in high 
cure  rates  and,  although  figures  are  variable, 
effectiveness  does  not  exceed  80%  at  the  one  year 
follow-up  [7].    Nevertheless  in  meta-analysis  studies, 
terbinafine  proved  to  be  superior  to  itraconazole  in 
efficacy, safety and drug interactions.8-10 Both are the 
most  widely  used  agents  for  the  treatment  of 
dermatophytic  onychomycosis;  itraconazole  is 
administered continuously or as pulses, and terbinafine is 
given  continuously  [7].  Approximately  20-25%  of  the 
patients  do  not  respond  to  initial  therapy  and  they 
frequently  switch  to  a  different  treatment.  An 
undetermined  percent  do  not  respond  to  any  of  the 
therapies and this may be due to various factors [11]. 
Original Articles / Prace Oryginalne  
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In a recent paper Gupta et al. [12] report the use of the 
itraconazole  and  terbinafine  combination  administered 
alternately  and  combined  in  patients  with 
chromoblastomycosis  refractory  to  various  treatments. 
Despite  the  small  number  of  patients  in  the  series, 
important improvement and cure were observed with the 
two-drug combination. The response might be due to a 
synergistic effect of the two drugs; we have also tried the 
combination successfully. Based on the former findings, 
this  study  enrolled  patients  with  dermatophytic 
onychomycosis  that  had  been  refractory  to  both 
medications given at the right dose and dosing schedule, 
this  time  using  an  alternate  weekly  treatment  regimen 
consisting of itraconazole and terbinafine. 
 
Material and methods 
This  is  a  prospective,  linear  clinical  trial  that 
enrolled  patients  with  clinically  and  mycologically 
proven dermatophyte-related onychomycosis of toenails. 
The patients included in the study were of both sexes, 18 
years of age and older, all of them signed a consenting 
form  to  go  in  to  the  trial;  all  patients  had  received 
previously  treatment  against  onychomycosis  and  never 
achieved cure (clinical and mycologic). All of them had 
previously been refractory to treatment with itraconazole 
and  terbinafine  given  at  the  right  doses  and  dosing 
schedules; itraconazole as 3 or more pulses (400 mg/day 
for one week) and terbinafine as continuous therapy for 3 
or more months (250 mg/day).  
This  means  that  patients  had  received  both  treatments 
during different periods and did not experience neither 
clinical  nor  mycologic  changes.  The  watch  out  time 
period with both therapy schemes was about 9 months 
after  the  last  dose,  because  this  is  the  minimum  time 
period to observe the action of both antifungal agents. 
Patients with immunosuppresive conditions or state were 
excluded, same as patients with other onychodystrophy-
related  disorders  (psoriasis).  Mycologic  tests  were 
performed consisting of KOH direct exam and culture in 
Sabouraud  dextrose  agar  and  Sabouraud  dextrose  agar 
with  antibiotics  (Mycobiotic).  Only  patients  with  a 
positive KOH and isolation of the causative agent were 
included in the study. 
The  treatment  regimen  consisted  in  terbinafine  and 
itraconazole administered in alternate weeks. This means 
that terbinafine 250mg/day was administered after lunch 
for one week, followed by itraconazole 200mg/day after 
lunch  in  the  following  week,  during  the  4  months  of 
treatment (Fig 1). 
Each  of  the  patients  underwent  a  complete 
blood  count  and  liver  function  tests  (alkaline 
phosphatase,  lactic  dehydrogenase  and  transaminases, 
TGO and TGP) at the onset, at two months and at the end 
of  the  treatment.  Clinical  follow-up  visits  took  place 
every  two  months  and  a  final  follow-up  visit  was 
scheduled  for  ten  months  after  the  last  drug 
administration,  i.e., one year and two months after the 
onset of the study. 
 
 
Figure 1. Scheme of treatment regimen 
 
 
 
Results 
We included 40 patients that fulfill the selection 
criteria, 8 patients were excluded of the study due to the 
lack of compliance to the therapy during the follow-up 
time period. Thirty-two patients who met the inclusion 
criteria  and  who  had  previously  failed  both  treatments 
(itraconazole and terbinafine) were enrolled in this study, 
during 2 years and two months period (between August 
2006 and September 2008). Figure 1 shows the patients’  
 
treatment regimen. The 32 patients comprised 18 females 
and 14 males; the youngest patient was 32 years old and 
the  oldest  68;  mean  age  was  45.6  years.  The  minimal 
period of wait after the last medication was 9 months and 
the maximal was 1.5 years, with 11.5 months average. 
Clinically,  28  (87.5%)  patients  had  distal  subungual 
onychomycosis  (DSO),  and  4  (12.5%)  had  total 
dystrophic  onychomycosis  (TDO).  In  all  patients  the 
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direct  exam  showed  filaments  and  the  causative  agent 
isolated in all cases was Trichophyton rubrum. One case 
had a mixture: T. rubrum plus Candida parapsilosis. 
At the end of the follow-up (10 months after the last drug 
administration),  17  patients  (53.12%)  had  clinical  and 
mycologic  cure,  15  of  them  had  DSO  and  2  TDO;  5 
patients (15.62%) had only clinical improvement, all of 
them with DSO, and 10 patients failure (31.25%) did not 
have neither clinical nor mycologic improvement, 8 of 
them  had  DSO  and  2  TDO.  Concerning  patients  with 
diabetes  mellitus,  3  attained  cure  (clinical  and 
mycologic) and 2 failed (Fig 2). 
No  changes  in  the  blood  count  and  the  liver  function 
tests  were  seen  during  the  trial.  Two  patients  reported 
side effects (6.25%), one of them had mild headache that 
lasted  two  days  and  the  other  one  had  moderate 
dysgeusia for 7 days. None of them warranted stopping 
the treatment.  
 
 
Figure 2. Example of treatment sequence 
 
 
Discussion 
The treatment of onychomycosis has changed as 
a result of the advent of new antifungal agents; however, 
this  disease  continues  to  be  a  problem  for  a  certain 
proportion of them. It is common that after failure of oral 
therapy,  patients  try  a  different  treatment;  they  may 
sometimes  try  topical  therapy  or  switch  to  a  different 
systemic  therapy.  In  general  and  according  with  the 
meta-analysis  studies,  the  best  response  to  the  oral 
treatment is obtained with terbinafine, which is superior 
to other oral antifungal agents [11-13]. There is thus an 
important  number  of  patients  who  have  failed  the  two 
most  widely  used  drugs  (itraconazole  and  terbinafine), 
even if given at the right dose and treatment duration. It 
is  difficult  to  find  the  reason  for  the  failure  of  both 
therapies,  but  some  factors  involved  may  be  poor 
absorption  of  the  drugs  in  the  GI  tract,  patient  non-
compliance or probable fungal resistance to antifungals. 
The latter has not been proven and most in vitro studies 
only  report  the  MIC  ranges  for  the  various 
dermatophytes [4,6,7]. 
This study stemmed from a publication by Gupta et al 
[12]  that  reported  cases  of  chromoblastomycosis  that 
responded poorly. Since we have had good results with 
this  therapy,  we  decided  to  extrapolate  it  to  cases  of 
onychomycosis  that  did  not  respond  to  standard 
therapies.  Even  though  the  behavior  of  dermatophytes 
differs from that of dematiaceous fungi such as Fosecaea 
pedrosoi,  we  thought  that  both  might  share  the  same 
bases for the likely synergistic effect of these drugs. 
The  results  of  this  study  indicate  that  clinical  and 
mycologic cure was obtained in 17/32 (53.12%) cases, 
meaning  that  more  than  half  of  the  cases  that  had 
previously  used  both  drugs  were  rescued.  However, 
15.6% of them only achieved clinical improvement and 
no mycologic cure, and approximately one third of the 
cases had no change. Concerning onychomycosis related 
to type 2 diabetes mellitus, 5 cases were included, 3 of 
which  attained  clinical  and  mycologic  cure,  indicating 
that  most  cases  showed  good  treatment  response. 
Nevertheless, we think that a specific study of patients 
with  this  condition  who  are  refractory  to  the  available 
treatments  for  onychomycosis  is  warranted  to  have  a 
better idea of their response to this combination therapy. 
Considering the response as it relates to the clinical form, 
since most cases were DSO, they responded to treatment 
as  well  as  2/4  cases  of  TDO.  This  indicates  that 
regardless of the clinical form of the disease, treatment 
response  did  occur  in  both  types  of  onychomycosis 
[1,4,5]. 
A self-criticism of this study is that it should have been 
conducted together with an in vitro study to determine 
the  initial  MICs  and  compare  them  with  the  clinical 
treatment response. 
Various  in  vitro  studies,  like  the  one  by  Santos  & 
Hamdan,[13] show that the MIC for the two drugs with 
the best results against the dermatophytes Trichophyton 
rubrum and Trichophyton mentagrophytes, is 0.031-0.5 
 g/ml for itraconazole  and <0.031  g/ml for terbinafine, 
and various authors think that the ranges of those MICs 
are  appropriate  for  the  treatment  of  onychomycosis. 
Although  these  results  are  similar  to  those  of  other 
studies, higher values are reported for some strains [14-
16]. 
Although the cure rates with the weekly alternate therapy 
with itraconazole plus terbinafine are considered as low, 
it is important to stress the fact that those were salvage 
cases.  The  two-drug  combination  might  have  a 
synergistic  effect,  as  happened  in  the  treatment  of 
chromoblastomycosis [12]. We did not find any in vitro 
studies in the literature indicating a synergistic effect of 
the  two  drugs,  particularly  against  dermatophytes, 
particularly Trichophyton rubrum. However, a series of 
studies  indicates  that  the  combination  of  triazoles 
(fluconazole and itraconazole) + terbinafine may have a 
synergistic effect. For example, this combination has had 
a  possible  synergistic  effect  against  Candida  albicans 
strains  that,  in  turn,  has  resulted  in  a  decrease  in  the 
minimum  inhibitory  concentration  for  both  triazoles 
[17,18].  Other  studies  indicate  that  the  itraconazole  + 
terbinafine  combination  may  also  have  a  synergistic 
action  against  Aspergillus  fumigatus  [19]  and 
Scedosporium  prolificans  strains  [20].  More  recently, 
Gómez-López et al [21] also reported synergistic effects 
of this combination against several Zygomycete species. 
In  vitro  synergy  was  shown  recently  when  terbinafine 
was  combined  with  itraconazole  and  voriconazole 
against Pythium insidiosum strains [22]. In conclusion, 
there is a series of filamentous and yeast fungi in which a 
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direct and synergistic effect has been proven and this is 
probably what happens with dermatophytes as well [23]. 
The  use  of  weekly  alternate  therapy  with  itraconazole 
and  terbinafine  is  possible  because  both  drugs  have 
particular  pharmacokinetic  properties;  both  are  depot 
drugs, especially at the stratum corneum level, so when 
given at the right doses they remain in the nails for long 
periods  of  time.  More  specifically,  the  plasma 
elimination  half-life  is  21  ±  5  hours  for  itraconazole 
200mg [12,24] and 22 hours for terbinafine 250mg [25]. 
It is important to underscore that both drugs remain in 
plasma for short periods of time and they are deposited 
in  the  stratum  corneum,  where  their  concentration 
increases  and  thus  allows  them  to  act  directly  on 
dermatophytes. 
It is important to emphasize that during the 4 months of 
treatment  (two  with  itraconazole  and  two  with 
terbinafine)  no  changes  in  laboratory  test  results 
occurred, especially in liver function tests, given that all 
patients remained within the normal ranges. Side effects 
occurred  in  two  patients  (6.25%);  one  had  moderate 
headache  and  the  other  one  mild  loss  of  taste 
(dysgeusia).  Both  effects  have  been  reported  for  both 
drugs  and  are  considered  as  minor;  treatment 
discontinuation was not necessary [5,7,24,26]. 
It  is  important  to  emphasize  that  this  is  a  clinical-
therapeutic report, and we consider it as a pilot study. 
Undoubtedly  the  critiques  of  this  study  consists  of 
several points: In the future is necessary to have in vitro 
studies to value the MIC of the etiologic agents and to 
compare  one  or  two  control  groups,  as  well  as  the 
possibility  to  make  this  a  randomized  trial,  this  will 
result in precise information about the effectiveness of 
the  double  therapy;  the  evaluation  of  the  placebo 
percentage and a broad sample (n) will avoid to consider 
the  results  are  owed  at  random.  In  our  criteria,  we 
continue  considering  the  oral  monotherapy  as  the  first 
choice of treatment. It is important to highlight that this 
study would be statistically more accurate with a control 
group, however as the patients are refractory to therapies 
is difficult to create a control group using monotherapy, 
that is why conclusions are basically descriptive. Despite 
the small number of cases, this study shows that around 
half of the cases may be rescued and it is important to 
emphasize that we do not have new medications to offer 
to  the  onychomycosis  refractory  cases.  In  general, this 
study might be considered as a pilot or pioneer study, 
which  brings  a  new  hypothesis  for  future  studies  with 
randomized inclusion of cases. 
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